Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

UK Approves Booster Doses For Two COVID-19 Vaccines

Executive Summary

AstraZeneca's Vaxzevria and Pfizer/BioNTech's vaccine can be used as "booster" vaccines in the UK, pending advice on a possible vaccination campaign from the government's advisory committee. 

You may also be interested in...



Coronavirus Notebook: Nobel Laureates Press Germany To Back Vaccine IP Waiver

The EU vaunts its vaccine donations and starts building resilience against future health threats, and the UK MHRA says Moderna can be used as a booster dose. Aviptadil has received scientific advice from the MHRA for its potential use as a treatment for COVID-19 patients.

WHO Urges Pause On COVID-19 Booster Shots

The pharmaceutical industry group, IFPMA, believes that a massive scale-up in manufacturing means booster shots will not necessarily “exacerbate inequities”.

EMA 'Confident' Of New COVID-19 Vaccine Approvals By Year End

The European drugs regulator has given an overview of progress with the assessment of new vaccine candidates, additional and booster vaccines, and the use of vaccines in younger age groups.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS144920

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel